Published online Jul 26, 2021. doi: 10.12998/wjcc.v9.i21.6091
Peer-review started: March 22, 2021
First decision: April 29, 2021
Revised: May 9, 2021
Accepted: May 26, 2021
Article in press: May 26, 2021
Published online: July 26, 2021
Congenital factor VII deficiency (FVIID) is a rare autosomal recessive genetic disorder. The clinical manifestations of this deficiency vary greatly. Predicting the risk of bleeding during and after childbirth of pregnant women with congenital FVIID is difficult. Recombinant factor VIIa is the most common replacement therapy for FVIID. However, no unified diagnosis and treatment plan for pregnant women with congenital FVIID has been established.
We report the clinical history of a pregnant woman who was considered to have congenital FVIID. Recombinant factor VIIa was prophylactically administered to the pregnant woman at the time of cervical fully opening. She successfully delivered a live infant without any complications, such as postpartum hemorr
Prophylaxis of recombinant factor VIIa during delivery can effectively reduce the incidence of postpartum hemorrhage among pregnant women with congenital FVIID associated with a high risk of bleeding.
Core Tip: The clinical manifestations of congenital factor VII deficiency vary greatly and range from a mild asymptomatic case to fatal bleeding. During pregnancy, predicting the risk of bleeding during and after childbirth of pregnant women with congenital factor VII deficiency is difficult, causing serious challenges to obstetricians and gynecologists. We hereby report a case of a pregnant woman with congenital factor VII deficiency and discuss the perinatal period and delivery management of this disease.